You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,700,530


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,700,530
Title:Capsule dosage form of metoprolol succinate
Abstract: This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL.RTM. tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.
Inventor(s): Vats; Sandeep Kumar (Sonipat, IN), Mondal; Balaram (East Midnapore, IN), Ramaraju; Kalaiselvan (Tiruchirappalli, IN), Singh; Romi Barat (Benares, IN)
Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED (Mumbai, IN)
Application Number:15/337,611
Patent Claims: 1. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, wherein the coated discrete units, after dispersing in an aqueous media for at least 10 minutes, have a desired flowability when passed through a feeding tube and contain not more than 0.50% by weight of the related substances of metoprolol succinate.

2. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units have d.sub.90 value from about 0.2 mm to 1.2 mm.

3. The extended-release capsule dosage form according to claim 1, wherein the particle size of the coated discrete units does not change more than 30% when exposed to an aqueous media for at least 10 minutes.

4. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units have d.sub.90 value between about 0.2 mm to 1.2 mm, wherein the coated discrete units when dispersed in aqueous media and delivered through a feeding tube having size NLT 10 F, at least 85% of metoprolol succinate is recovered at the exit of feeding tube after holding for at least 10 minutes.

5. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are in the form of a plurality of pellets, granules, minitablets, or beads.

6. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are lubricated before filling into the capsule.

7. The extended-release capsule dosage form according to claim 6, wherein the lubricant is selected from the group consisting of colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and mixtures thereof.

8. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are administered by a feeding tube selected from the group consisting of NG tube, G tube, and J tube.

9. The extended-release capsule dosage form according to claim 8, wherein the coated discrete units are dispersed in an aqueous media in a latex-free syringe and subsequently delivered through a feeding tube.

10. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, wherein the coated discrete units, when sprinkled on soft foods having different pH levels and exposed for at least 30 minutes, contain not more than 0.50% by weight of the total related substances of metoprolol succinate.

11. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, which, when sprinkled onto soft foods, produces a dissolution profile of metoprolol succinate similar before and after exposure for at least 30 minutes to soft foods having different pH levels.

12. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are in the form of a plurality of pellets, granules, minitablets, or beads.

13. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are lubricated before filling into the capsule.

14. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are administered by a feeding tube selected from the group consisting of NG tube, G tube, and J tube.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.